Sourcing, verification, documentation, storage, handling, labeling, and fulfillment vary substantially across suppliers, especially in the research-use-only (RUO) market. RUO peptides are sold and labeled for laboratory research, not as FDA-approved peptides. They sit in a different regulatory category from prescription medicines like Wegovy and Mounjaro, and the trust signal comes from the manufacturing chain (purity testing, batch documentation, lab verification) rather than from an FDA-approval stamp.

Two vials labeled "semaglutide" can come from very different supply chains with very different verification standards.

The FDA has published specific concerns about unapproved GLP-1 products: dosing errors, fraudulent products, mismatches in the form of the molecule (the salt form, where different chemical pairings of the active ingredient with a stabilizer affect both the dose math and the stability), labeling problems, and quality-control gaps.

The molecule's name on the vial doesn't carry information about any of those.